Patents by Inventor Jane Spetzler

Jane Spetzler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Insulin and IGF-1 Receptor Agonists and Antagonists
    Publication number: 20090192072
    Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.
    Type: Application
    Filed: November 21, 2008
    Publication date: July 30, 2009
    Applicants: Novo Nordisk A/S, Antyra Inc. (formerly DGI Bio Technologies)
    Inventors: Renuka Pillutla, Renee Brissette, Arthur J. Blume, Lauge Schaffer, Jacob Brandt, Neil I. Goldstein, Jane Spetzler, Soren Ostergaard, Per Hertz Hansen
  • Dimeric Peptide Agonists of the Glp-1 Receptor
    Publication number: 20090062192
    Abstract: Dimerization of GLP-1 agonists and therapeutic uses thereof.
    Type: Application
    Filed: March 20, 2006
    Publication date: March 5, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Leif Christensen, Jesper Lau, Jane Spetzler, Thomas Kruse Hansen
  • INSULIN AND IGF-1 RECEPTOR AGONISTS AND ANTAGONISTS
    Publication number: 20070265189
    Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.
    Type: Application
    Filed: July 10, 2007
    Publication date: November 15, 2007
    Applicants: Novo Nordisk A/S, Antyra Inc.
    Inventors: Renuka Pillutla, Renee Brissette, Arthur Blume, Lauge Schaffer, Jakob Brandt, Neil Goldstein, Jane Spetzler, Soren Ostergaard, Per Hansen
  • Insulin and IGF-1 receptor agonists and antagonists
    Patent number: 6875741
    Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: April 5, 2005
    Inventors: Renuka Pillutla, Renee Brissette, Arthur J. Blume, Lauge Schäffer, Jakob Brandt, Neil I. Goldstein, Jane Spetzler, Søren Østergaard, Per Hertz Hansen
  • Isulin and IGF-1 receptor agonists and antagonists
    Publication number: 20030236190
    Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.
    Type: Application
    Filed: September 24, 2002
    Publication date: December 25, 2003
    Inventors: Renuka Pillutla, Renee Brissette, Arthur J. Blume, Lauge Schaffer, Jacob Brandt, Neil I. Goldstein, Jane Spetzler, Soren Ostergaard, Per Hertz Hansen
  • Insulin and IGF-1 receptor agonists and antagonists
    Publication number: 20030195147
    Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.
    Type: Application
    Filed: September 24, 2001
    Publication date: October 16, 2003
    Inventors: Renuka Pillutla, Renee Brissette, Arthur J. Blume, Lauge Schaffer, Jakob Brandt, Neil I. Goldstein, Jane Spetzler, Soren Ostergaard, Per Hertz Hansen